ERBB2 and cancer: We chose this set of cell lines as they cover all the major breast cancer tumour subtypes (LuminalA/LuminalB/Her2-enriched/Basal Like) and are extensively used in cancer research and in drug development, while also being fully characterized both at the genomic and (bulk) transcriptomic level, as well as in terms of drug response7,8,22,23.